Endo Reports Findings From PK Simulation Modeling Study In Men With Hypogonadism

Endo International plc (ENDP) published data from a population pharmacokinetic modeling and simulation study, evaluating potential dosing flexibility of AVEED (testosterone undecanoate) in hypogonadal males. The company said the pharmacokinetic simulation modeling study predicted more frequent administration with shorter dosing intervals (8 weeks vs. 10 weeks) would reduce serum testosterone fluctuations and elevate testosterone concentrations at the end of each maintenance dosing interval while maintaining acceptable levels of overall testosterone exposure.

AVEED is indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Tesla Inc. founder and CEO Elon Musk has sold some of his stake in the luxury electric car maker to avoid an emergency sale of its stock in the event of a forceful Twitter deal. Twitter Inc. and Tesla shares were gaining more than 4 percent in the pre-market activity on the NYSE and Nasdaq, respectively, following the news. Meta Platforms Inc., the parent of Facebook, Instagram, and WhatsApp, has added three more new privacy features to WhatsApp in its bid to enhance control and privacy on the popular messaging app. These features will give the user more control over their messages with added interlocking layers of protection. Insurance company Prudential plc reported Wednesday a sharp drop in first-half pre-tax profit. On an after-tax basis, the company recorded a profit, compared to last year's hefty loss, due to the absence of prior year's loss from discontinued operations. Separately, Prudential announced its 2022 first interim dividend of 5.74 US cents per ordinary share, which will be paid on September 27.
Follow RTT